Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Its pipeline includes clinical and pre-clinical product candidates with mechanisms of action and novel chemical structures. The company's product candidates in clinical development include Azixa (MPC-6827), which is under Phase II clinical trial for the treatment of glioblastoma multiforme and metastatic melanoma; MPC-4326 for HIV-1 infection under Phase IIb clinical trial; and MPC-3100, a Phase I clinical trial product candidate for cancer treatment. Its products in preclinical programs comprise MPI-443803, an orally available, brain penetrant, microtubule destabilizing agent for the treatment of cancer; and MPI-461359, an orally available maturation inhibitor for the treatment of HIV-1 infection, as well as MPI-479605 for the treatment of cancer. The company also offers ProNet, a proprietary database of protein-protein interactions, which encompasses interactions between approximately 10 million protein fragments constructed from various organ tissues, including heart, brain, kidney, liver, breast, and prostate. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.

Warner Chilcott plc company was founded in 1968 and is headquartered in Rockaway, New Jersey. Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women’s healthcare and dermatology segments of the United States pharmaceutical market. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. In October 2009, the Company announced it completed the acquisition of The Procter & Gamble Company’s global branded prescription pharmaceutical business.

Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction and obsessive-compulsive disorders. Its products include CPP-109, a chemical compound gamma-vinyl-GABA/vigabatrin, a Phase II clinical trial product for the treatment of cocaine addiction. The company also conducts a Phase II clinical trial of CPP-109 to evaluate its use in the treatment of methamphetamine addiction. In addition, it has a license agreement with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions.

Galderma Laboratories, L.P., a dermatology company, engages in the research, development, and marketing of dermatology products. Its pharmaceutical and over-the-counter products include Differin, which is used to treat acne; MetroGel, MetroLotion, and MetroCream, to treat rosacea; Clobex lotion, which helps in controlling and treating moderate-to-severe plaque psoriasis; and Cetaphil, a line of cleansers and moisturizers. The company has operations in North America, Western Europe, Latin America, Asia, Australia, and Africa. It offers its services directly, and through sales representatives, as well as through special programs. The company was founded in 1961 as Owen Laboratories and changed its name to Galderma Laboratories, L.P. in 1981. The company is headquartered in Fort Worth, Texas. Galderma Laboratories, L.P. operates as a subsidiary of Galderma SA.

De Novo Pharmaceuticals, Ltd. was incorporated in 1999 and is based in Cambridge, the United Kingdom. De Novo Pharmaceuticals, Ltd., a drug discovery company, provides computational drug design services. It focuses on small molecule therapeutics. The company provides services to drug discovery customers seeking progress from validated target to novel hits; and to medicinal chemistry groups interested in focused chemical libraries. It offers SkelGen, a chemical structure-generation platform and a suite of software tools for the analysis of structural information on a protein target and the de novo design of molecules to bind into its site, as well as for the hit and lead discovery to the pharmaceutical industry. The company offers its SkelGen for scaffold hopping, virtual high-throughput screening, focused library design, intelligent fragment linking, and low affinity fragment-based design applications. It also provides drug discovery partnerships, such as structure-based drug design, ligand-based drug design, and fragment-based drug design services, as well as focused libraries for medicinal chemistry seeking the design of focused libraries against classes of targets. In addition, the company involves in applying its SkelGen silico drug design platform to design compounds for various targets within the diabetes field.

American Bio Medica Corporation develops, manufactures, and sells immunoassay diagnostic test kits for the point of collection testing (POCT) for drugs of abuse in North America, Europe, the Asia/Pacific Rim, Africa, and South America. Its products include Rapid Drug Screen, a POCT kit to detect the presence or absence of 2 to 10 drugs of abuse in a single urine specimen; Rapid One, which screens for the presence or absence of a single drug of abuse in a urine specimen; Rapid TEC that contains 1 or 2 drug testing strips to test for 2 to 5 drugs of abuse in a single urine specimen; RDS InCup, a POCT for 2 to 12 drugs of abuse that incorporate collection and testing of sample in a device; Rapid TOX, a drug screen that detects 2 to 10 drugs of abuse in a single urine specimen; and Rapid TOX Cup, a POCT for 2 to 14 drugs of abuse that incorporate collection and testing of sample in a single device.American Bio Medica Corporation company’s products also include OralStat, a POCT system to detect drugs of abuse in oral fluids; OralStat EX, an oral fluid POCT for point of collection testing and confirmation testing; and Rapid STAT, an oral fluid POCT. In addition, it offers Rapid Reader, a compact and portable device that captures a picture of the test results on an ABMC drug screen. Further, American Bio distributes various POCTs to detect the presence or absence of adulterants, alcohol, and nicotine; and provides bulk strip contract manufacturing services to non-affiliated POCT diagnostic companies. It offers products for employers, law enforcement, government, health care, laboratory, and education professionals to test for cocaine, THC, opiates, amphetamines, PCP, benzodiazepines, methamphetamines, barbiturates, tricyclic antidepressants, methadone, oxycodone, propoxyphene, and buprenorphine. The company was formerly known as American Micro Media, Inc and changed its name to American Bio Medica Corporation in September 1992. The company was founded in 1986 and is based in Kinderhook, New York.

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications and vitamin drops. The Health Care segment is engaged in the manufacture and sale of general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. The Company has 49 subsidiaries and 15 associated companies.

Symbollon is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its I2 technology. I2 is the chemical symbol for molecular iodine. Molecular iodine is the active species of iodine, a proven fast acting, broad-spectrum antimicrobial and therapeutic. Formed in 1986, Symbollon completed its initial public offering in December 1993. Since that time we have pursued product applications for our technology in two distinct areas; women’s healthcare and antimicrobial applications.In female health, Symbollon has developed a proprietary oral tablet based on our technology that generates I2 in situ (the stomach of the patient). We refer to this drug as IoGen. In 2000, Symbollon completed Phase I and II clinical trials evaluating IoGen as a potential treatment for fibrocystic breast disease. Phase III pivotal trials will be conducted in 2005. We believe that IoGen may also be useful for the treatment and prevention of other types of excess cell growth in female reproductive tissue, such as endometriosis, ovarian cysts and pre-menopausal breast cancer.

Phase 2 Discovery partners with pharmaceutical companies to develop early-stage drug candidates that could treat various central nervous system diseases and conditions. The company also acquires drug candidates, takes them through Phase I and II clinical studies, and then offers the company the option of re-acquiring them Phase 2's goal is to speed up the discovery process for multiple compounds that could aid patients with psychiatric and neurological disorders.

Galapagos has formed its own archipelago of drugs to treat bone and joint ailments and other diseases. The company uses its proprietary genomic drug-discovery technology to develop medicines to treat rheumatoid arthritis, osteoarthritis, and osteoporosis. Galapagos' pharma services subsidiaryBioFocus DPI offers collaborative drug-discovery services to other pharmaceutical companies. Its drug discovery division works with partners to find, test, and market new drugs. The company's pharmaceutical collaborators include top drugmakers GlaxoSmithKline, Eli Lilly, Merck, and Janssen Pharmaceutica, part of Johnson & Johnson. Galapagos has about 40 projects in its R&D pipeline, most of them through these partnerships.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.